O
RGEN icon

OrbiMed’s Repligen RGEN Stock Holding History

OrbiMed’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,724
Closed -$4.25M – 176
2021
Q3 		$4.25M Buy
+14,724
New +$3.78M 0.05% 155

Other funds holding RGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed's RGEN Position: Q4 2021 in Review

OrbiMed sold out of Repligen (RGEN) in Q4 2021, closing a stake of 14,724 shares — an estimated $4.25M sold.

OrbiMed first reported a position in RGEN in Q3 2021 and held it in 1 quarter. The position peaked at $4.25M in Q3 2021. 507 funds tracked by Wall St. Rank hold RGEN as of Q4 2021.

  • OrbiMed reported no remaining Repligen position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 14,724 Repligen shares in Q4 2021, an estimated $4.25M.
  • OrbiMed first reported a position in Repligen in Q3 2021 and held it in 1 quarter.
  • OrbiMed's Repligen position peaked at $4.25M in Q3 2021.
  • 507 funds tracked by Wall St. Rank held Repligen as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.